CD20, a transmembrane calcium channel required for B cell activation, proliferation, and differentiation, has emerged as a key therapeutic target for B-cell malignancies and autoimmune disorders ...

ATOM is now well poised to continue to the upside as trading volume tripled over the past 24 hours, indicating optimism from ...

CD20 expression levels were associated with patient outcomes following treatment with bispecific CD20xCD3 antibodies in patients with B-cell lymphomas in a new study. The findings, which were ...

Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies. Blood, 2023; 142 (20): 1724 DOI: 10.1182/blood.2023020400; ...

The review concludes that CD20-targeted chimeric antigen receptor (CAR) T-cell therapy is an option worth exploring, despite potential safety concerns that warrant more extensive research.

Allogeneic BCMA or dual-targeting CD19/CD20 CAR-T cells developed using this platform exhibit robust antitumor activity in the presence of NK cells, indicating that THANK-u Plus™ has broad ...

TG Therapeutics sees growth from BRIUMVI’s MS launch, but competition, pipeline risks, and valuation concerns limit upside.

“Anti-CD20 Monoclonal Antibodies Market” from 2024-2034 with covered segments (By Product Type (First Generation Anti-CD20 Monoclonal Antibodies, Second Generation Anti-CD20 Monoclonal ...

Arthritis & Rheumatism. 2008;58(6):1566-1575. B cells, precursors of autoantibody-secreting cells, have emerged as promising new therapeutic targets in autoimmune diseases, including ...

In patients with myasthenia gravis (MG) who had anti-acetylcholine receptor antibodies or anti-muscle-specific kinase ...

While the CD20 is down over 3% in the last 24-hour period, tokens including PAXG and XAUT are up 0.7% to over $3,100. These tokens are up more than 18% year-to-date, while BTC is down 12.5% and ...

IMPT-514 is a bispecific CD19/CD20-targeting chimeric antigen receptor T-cell therapy. The Food and Drug Administration (FDA) has granted Fast Track designation to IMPT-514, a bispecific CD19/CD20 ...